Both in Pharmaceuticals
Dianthus Therapeutics vs Erasca
Over the past year DNTH returned +158.5% and ERAS returned +545.5%; their daily moves had a correlation of 0.31.
DNTH +158.5% ERAS +545.5%Growth of $1, one year, split-adjusted
| Metric | DNTH | ERAS |
|---|---|---|
| Price | $85.81 | $14.91 |
| Market cap | $4.80B | $5.21B |
| Today | +3.76% | +1.84% |
| 1 month | +0.5% | +4.3% |
| 6 months | −5.1% | +36.8% |
| Year to date | +108.2% | +300.8% |
| 1 year | +152.2% | +526.5% |
| Revenue growth (YoY) | +294.3% | — |
| Gross margin | 100.0% | — |
| Net margin | −6598.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 2,520.9× | — |
| Net cash | $886.8M | $268.7M |
| Dividend yield | — | — |
| Volatility (60d) | 38.9% | 59.7% |
| Short % of float | 18.4% | 14.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).